
Novel CRS Prevention Therapy Granted FDA Orphan Drug Designation
The FDA has granted orphan drug designation (ODD) to POLB 001. POLB 001 is an oral preventative therapy for bispecific T-cell engager (BiTE) therapy-induced cytokine release syndrome (CRS). The first patient is expected to be dosed with POLB 001 in a phase …